Here are the 424B prospectus supplements from GeoVax Labs, Inc. Warrants (GOVXW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow GOVXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVXW filings page.
GeoVax Labs, Inc. is registering 402,000 shares of common stock and 30,902 pre-funded warrants, plus 30,902 shares issuable upon their exercise, in a public offering priced at $2.31 per share and $2.30999 per pre-funded warrant. Gross proceeds are expected to be about $1,000,003.31, with estimated net proceeds of approximately $865,000 after placement fees and expenses.
The company will use the funds to advance its vaccine and immunotherapy pipeline, including COVID-19 candidate GEO-CM04S1, oncology therapy Gedeptin and Mpox/smallpox vaccine GEO-MVA, as well as for manufacturing, clinical studies, capital spending and working capital. A concurrent private placement will issue 865,804 unregistered common warrants exercisable at $2.31, which could provide additional cash if exercised.
GeoVax Labs, Inc. files a prospectus supplement that currently permits additional at-the-market sales of its common stock of up to approximately $3,116,227 through A.G.P./Alliance Global Partners under an existing Form S-3 program. This updates an earlier $30,000,000 at-the-market facility under which the company has already sold 4,525,449 shares for $9,269,560.
The supplement reflects limits under General Instruction I.B.6 of Form S-3, tied to GeoVax’s public float. The aggregate market value of common stock held by non-affiliates is stated as $17,804,611, based on 1,728,603 non-affiliate shares at $10.30 per share as of December 8, 2025, and the company notes it has raised $2,818,643 under this instruction in the past twelve months. GeoVax’s stock trades on the Nasdaq Capital Market under the symbol GOVX, with a last reported price of $3.15 on January 23, 2026.